Contribution to Research and Charity
The potential for Immune Formulation 200© to impact the body’s ability to produce glutathione on an intracellular level has become the subject of a License donation to the Program Directors Association of Research Centers in Minority Institutions (RCMI). RCMI, a consortium of 18 medical research institutions, has committed $17.5M annually, funded by the National Institutes of Health (NIH), after their initial study of ProImmune©, to research and conduct clinical studies on oxidative stress, and ProImmune©’s influence on various aspects of health including aging. The contract is for five (5) years and a total of $87,500,000.00.
Drew University of Medicine and Science in partnership with a team from the Laboratory of the David Geffin School of Medicine UCLA reported the results of its first study at a meeting of the American Federation for Medical Research in Carmel, CA, February 2008 (see Research Results page).
RCMI has committed $17.5 million/year for research to study, learn, understand and define the effectiveness of Immune Formulation 200© in increasing bodily Glutathione levels.
This commitment underscores the medical research community’s belief in the revolutionary potential of the antioxidant benefits to be derived from Immune Formulation 200©.
In addition, in their commitment, RCMI underscores their interest with the economic dimension this discovery could provide.
Dr. Crum has donated the five Licenses for Immune Formation 200© to RCMI to facilitate this important, far reaching immune support research.